stockrowSiga Technologies Inc.
SIGA Healthcare Drug Manufacturers Specialty & Generic
Siga Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $94.6 million, down 31.8% from fiscal 2024.
- Revenue
- −49.5%
- EPS
- −66.0%
- Free cash flow
- −76.0%
Quarter to June 2026, against a year earlier
Follow SIGA
Alert me
Siga Technologies Inc. (SIGA) EV/Sales
As of 5 November 2026, Siga Technologies Inc. (SIGA) trades at a EV/Sales of 4.7×. Over the past ten years it has ranged from −22.8× (December 2015) to 98.9× (August 2018); the current reading is higher than 54% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.9× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.7× | 49.81% |
| FY2024 | 3.1× | 2.69% |
| FY2023 | 3.0× | (41.38%) |
| FY2022 | 5.2× | 11.09% |
| FY2021 | 4.7× | (5.77%) |
| FY2020 | 4.9× | (65.64%) |
| FY2019 | 14.4× | 1,049.20% |
| FY2018 | 1.3× | (96.35%) |
| FY2017 | 34.3× | 160.75% |
| FY2016 | 13.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.6× | 33.28% |
| Mar 2026 | 4.2× | (9.28%) |
| Dec 2025 | 4.7× | 25.08% |
| Sep 2025 | 3.7× | 51.37% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BIOA BioAge Labs, Inc. compare | −7.2× |
| AKBA Akebia Therapeutics, Inc. compare | 0.1× |
| EBS Emergent Biosolutions Inc. compare | 1.0× |
| CGC Canopy Growth Corporation compare | 1.0× |
| GLAS Glass House Brands Inc. compare | 1.4× |
| ADCT ADC Therapeutics SA compare | 1.9× |
| ANIK Anika Therapeutics Inc. compare | 2.0× |
| LFCR Lifecore Biomedical, Inc. compare | 3.6× |
| SIGA Siga Technologies Inc. | 4.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)